Caris Life Sciences
Caris Life Sciences' revenue rose 97.0% to $812 million in fiscal 2025. Its operating margin was 5.6%, up from −62.4% a year earlier. Free cash flow was $67 million. It paid out $0 million in dividends and buybacks, 0% of free cash flow. The diluted share count rose 371.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Caris Life Sciences does
Caris Life Sciences runs laboratory tests that read the genetic makeup of a patient's cancer, with the aim of helping doctors choose treatments. It is also a data company: it uses artificial intelligence on its large set of genetic and clinical data. It was founded in 2008, and as of December 31, 2025, it had sequenced over 1,000,000 cases.
Its Molecular Intelligence product line focuses on oncology and has three platforms: MI Profile (tissue-based tests), Caris Assure (blood-based tests) and the Precision Whole Genome Platform. It serves clinical, academic and drug-company (biopharma) customers. Doctors order its tests for patients. Biopharma and research partners also use its data and bioinformatics services to look for drug targets.
The company says its current revenue comes mainly from its tissue-based profiling solution. It received FDA approval in November 2024 for MI Cancer Seek, a test it launched in January 2025 and expects to drive growth. It expects to launch whole genome sequencing solutions in 2026.
Its biggest risks, as it describes them
- Competition in a precision medicine field that changes quickly.
- Losses since it was founded, and possibly not reaching profit.
- Needing coverage and adequate payment from Medicare and other insurers for its tests.
- Relying on tissue-based profiling for most revenue, and on doctors adopting MI Cancer Seek.
- Relying on a few or sole suppliers for sequencers and lab supplies.
Income statement
Caris Life Sciences lost money in fiscal 2025: a net loss of $68 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | — | 66 | 799 |
| Debt incl. finance leases | — | 374 | 379 |
| Net debt (negative means net cash) | — | 307 | −420 |
| Net debt to EBITDA | — | — | −6.2x |
| Debt to equity | — | — | 0.7x |
| Interest coverage | −10.1x | −5.1x | 0.8x |
| Current ratio | — | 1.3x | 7.8x |
| Quick ratio | — | 1.3x | 7.8x |
Cash flow
Projections
Project Caris Life Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Caris Life Sciences says to expect
- Full year 2026: revenue and test volume
Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.5 million of Caris Life Sciences shares on the open market, and 4 insiders sold $28.9 million, $1.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | John Russel DentonSee Remarks | Sold | 7,500 | $31.82 | $238,650 | Form 4 |
| Sep 17, 2026 | Brian J BrilleSee Remarks, Director | Sold | 400,000 | $30.33 | $12.1 million | Form 4 |
| Sep 4, 2026 | David Baxley SpetzlerPresident | Sold | 119,212 | $24.76 | $3.0 million | Form 4 |
| Sep 3, 2026 | David Baxley SpetzlerPresident | Sold | 478,000 | $24.86 | $11.9 million | Form 4 |
| May 15, 2026 | Jon HalbertDirector | Bought | 68,000 | $14.56 | $990,080 | Form 4 |
| May 11, 2026 | Jeff L VacircaDirector | Bought | 31,050 | $16.15 | $501,457 | Form 4 |
| Dec 11, 2025 | Luke Thomas PowerSee Remarks | Sold plan | 62,250 | $26.57 | $1.7 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −26.9% | 105.2% |
| Altman Z'' | −31.74 | −0.93 |
| Accruals ratio | — | −20.6% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | Fail |
| Cash from operations is positive | Fail | Pass |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Caris Life Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Caris Life Sciences | FY25 | 97.0% | 5.6% | 8.2% | — | −6.2x | — | |
| Myriad Genetics | FY25 | −1.6% | −47.0% | −1.7% | −62.6% | — | 5 | Compare |
| NeoGenomics Laboratories | FY25 | 10.1% | −15.9% | −3.0% | −8.8% | — | 5 | Compare |
| Pennant Group | FY25 | 36.3% | 5.5% | 3.8% | 9.3% | 2.6x | 5 | Compare |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 306 | 412 | 812 |
| Revenue growth | — | 34.7% | 97.0% |
| Gross profit | — | — | — |
| Research and development | 117 | 114 | 102 |
| Operating income | −320 | −257 | 45 |
| Net income | −341 | −282 | −68 |
| Diluted EPS (US$) | −13.24 | −10.66 | −3.22 |
| Diluted shares (millions) | 35 | 36 | 167 |
| Cash flow | |||
| Cash from operations | −276 | −245 | 83 |
| Capital expenditure | 22 | 8 | 16 |
| Free cash flow | −298 | −254 | 67 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 15 | 19 | 70 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | — | 66 | 799 |
| Debt incl. finance leases | — | 374 | 379 |
| Total assets | — | 344 | 1,126 |
| Total liabilities | — | 621 | 548 |
| Shareholders' equity | −2,145 | −2,499 | 577 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −104.4% | −62.4% | 5.6% |
| Net margin | −111.5% | −68.4% | −8.4% |
| Free cash flow margin | −97.5% | −61.5% | 8.2% |
| Rule of 40 (growth + FCF margin) | — | −26.9% | 105.2% |
| Return on capital | — | — | — |
| Return on equity | — | — | — |
| Return on assets | — | — | −9.3% |
| Net debt to EBITDA | — | — | −6.2x |